Management of Uterine Fibroids
Management of uterine fibroids should be stratified by fertility desire, symptom type, fibroid location, and patient age, with medical management trialed first in most cases before proceeding to minimally invasive or surgical interventions. 1
Reproductive Age Patients Desiring Future Pregnancy
For patients with symptomatic fibroids who desire future fertility, laparoscopic or open myomectomy is the preferred surgical approach, as it preserves the uterus while addressing fibroid-related symptoms 1. However, less than half of patients achieve pregnancy after myomectomy at 3 years, and of those pregnancies, less than half result in live birth 1. Both laparoscopic and open myomectomy carry risk of uterine rupture in subsequent pregnancy 1.
- UAE can be considered as an alternative, with spontaneous pregnancy rates of 29.5% at 1 year and 40.1% at 2 years, and a live birth rate of 81% 1
- MRgFUS has limited evidence for fertility enhancement, with only case reports available and one randomized trial terminated due to lack of enrollment 1
- Medical management options are limited as most suppress fertility during treatment, though ulipristal acetate showed 41% fibroid volume reduction with pregnancy rates similar to controls without fibroids 1
Reproductive Age Patients Without Fertility Desires
For symptomatic patients not desiring pregnancy, laparoscopic/open myomectomy, medical management, MRgFUS, or UAE are equivalent first-line options, with medical management typically trialed first 1.
Medical Management Approach
First-line agents include estrogen-progestin oral contraceptives and progestin-containing IUDs for bleeding symptoms 1. Tranexamic acid serves as a nonhormonal alternative 1.
Second-line options include GnRH agonists (leuprolide) and antagonists (elagolix, linzagolix, relugolix), which reduce both bleeding and tumor volume 1. These agents cause hypoestrogenic effects (headaches, hot flashes, hypertension, bone mineral density loss), but combination treatment with low-dose estrogen-progestin mitigates these symptoms and is FDA-approved for fibroid-related heavy menstrual bleeding 1. A critical caveat: symptoms rapidly recur after cessation of therapy 1.
Minimally Invasive Procedures
UAE demonstrates superior outcomes compared to MRgFUS, with better symptom relief, improved quality of life, and lower reintervention rates 1. UAE causes persistent decreases in pain and heavy menstrual bleeding with average fibroid size reduction >50% at 5 years 1. Compared to myomectomy, UAE shows equivalent effectiveness for heavy menstrual bleeding at 4 years, with decreased blood transfusion risk, shorter hospital stays, and significantly lower rates of new fibroid formation 1. However, secondary hysterectomy rates reach 28% at 5 years and 35% at 10 years 1.
MRgFUS shows lower efficacy than UAE, with reintervention rates of 33% at 2 years in placebo-controlled trials 1. The procedure takes significantly longer (6.75 hours versus 2.3 hours for UAE) and is occasionally performed over 2 days 1. The major advantage is decreased postprocedural pain, reduced narcotic use, and faster recovery 1. A large prospective trial demonstrated major adverse event rates of only 0.2% for MRgFUS versus 12.6% for surgical approaches, with greater improvement in symptoms and quality of life at 6 and 12 months compared to surgery 1.
Specific Clinical Scenarios
Submucosal Fibroids with Heavy Bleeding
Hysteroscopic myomectomy or medical management is the appropriate initial therapy for pedunculated submucosal fibroids causing heavy bleeding 1. Hysteroscopic myomectomy provides shorter hospitalization and faster return to activities compared to laparoscopic/open approaches, with equivalent quality of life improvement at 2-3 months 1. Critical limitation: patients with significant intramural/subserosal fibroid burden or concomitant adenomyosis are less likely to benefit 1.
Fibroids with Concurrent Adenomyosis
Medical management or UAE is the preferred initial therapy for patients with fibroids and adenomyosis 1. This combination is particularly important to recognize, as treatment failure of endometrial ablation for heavy menstrual bleeding is associated with adenomyosis presence 1.
Postmenopausal Patients
Hysterectomy is the appropriate next step for postmenopausal patients with symptomatic fibroids and negative endometrial evaluation 1. Hysterectomy provides definitive resolution of all fibroid-related symptoms and eliminates risk of new fibroid formation 1. Important caveat: even with bilateral ovarian conservation, hysterectomy is associated with elevated cardiovascular disease risk, mood disorders, and increased mortality, especially when performed at young age 1.
Key Procedural Considerations
All patients should be counseled that pregnancy is possible after hysteroscopic myomectomy, laparoscopic/open myomectomy, LUAO, UAE, and MRgFUS, even when not desiring future fertility 1.
Laparoscopic approaches are associated with shorter hospital stays and faster return to activities compared to open myomectomy, with robotic-assisted laparoscopy showing similar outcomes to traditional laparoscopy 1. Open myomectomy is preferred for multiple fibroids or very large uteri 1.